Direct compression campaigns for N1,N2-didodecyloxalamide are initiated only after dry particle-size reduction because the as-received long-chain oxalamide contains agglomerates that impair blend uniformity under USP <905>. A cone mill fitted with a 0.8 mm stainless-steel screen and impeller speed of 2,500 rpm is used to co-mill the active with lactose monohydrate at a 1:1 w/w ratio. The co-milled fraction is then blended with silicified microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide in a 600 L bin blender at 9 rpm for 20 min. Lubrication with magnesium stearate is performed separately for 3 min because the long alkyl chains of the compound increase the risk of hydrophobic film formation on the blend when the lubricant is over-mixed. Tablet cores are compressed to an active content of 8.0% w/w on a rotary press operating at 40 rpm with compression force between 12 kN and 18 kN, producing cores with hardness from 60 N to 90 N and friability below 0.8% when tested according to Ph. Eur. 2.9.7. In-process control includes weight uniformity under Ph. Eur. 2.9.5, content uniformity under Ph. Eur. 2.9.40, and disintegration under USP <701>. The terminal dosage form is a film-coated immediate-release tablet; coating is applied in a perforated pan to a 2.0% to 3.0% weight gain using an aqueous polyvinyl alcohol-based system to reduce dusting without altering the dissolution profile. Aqueous coating remains permissible because the tablet core is not exposed to sustained moisture; however, processing at RH > 60% should be avoided due to static charging and reduced powder flow. Direct compression is limited to strengths where the active content does not exceed 15.0% w/w of the core; beyond that, the hydrophobic character of the compound reduces tensile strength and a wet-granulation or roller-compaction route is required.

What Controls Granule Porosity When the Compound Is Pre-Blended with Silicified Microcrystalline Cellulose?

Wet granulation introduces water, but the compound is hydrophobic and excludes water from intragranular pores; binder distribution therefore depends more on mixing order than on total granulation liquid volume. In high-shear wet granulation, the active is pre-blended for 5 min with silicified microcrystalline cellulose before binder addition. The binder solution contains povidone K30 at 4.0% w/w of total granulation mass and is sprayed until the granulation mass increases by 8.0% to 10.0%. Impeller tip speed is kept between 4.0 m/s and 5.5 m/s, with the chopper operated at 1,500 rpm for 1 min after the wet addition. Granulation endpoint is accepted only when impeller power consumption reaches 2.5 kW to 3.0 kW on a 65 L granulator, because overdried or overwet batches show a bimodal granule size distribution that causes segregation in the downstream compression feed frame. After wet massing, granules are dried in a fluid-bed dryer with inlet air at 55 °C until loss on drying is 1.2% to 1.8%. Dried granules are passed through a 1.25 mm oscillating mill and blended with extragranular croscarmellose sodium at 4.0% w/w and magnesium stearate at 0.5% w/w. Control of the elemental impurity profile is conducted according to ICH Q3D, with analytical confirmation by USP <232> and USP <233>; residual solvent testing is performed under USP <467> because the granulation does not use organic solvents. The final tablet is compressed to a drug load of 6.0% w/w and released under USP <711> and Ph. Eur. 2.9.40. The terminal product is an immediate-release tablet with a wet-granulated core; this route is selected when the direct compression blend shows poor flow or when the active content falls below 6.0% w/w and co-milling alone cannot provide content uniformity.

At production sites where the compound is intended for oral granules packed in stick-pack or sachet formats, dry granulation by roller compaction is selected to avoid residual-water-related agglomeration and to preserve the low bulk density required for fast reconstitution. The blend is prepared with 12.5% w/w active, 35.0% w/w mannitol, 30.0% w/w pregelatinized starch, 10.0% w/w xylitol, 2.0% w/w crospovidone, and 0.5% w/w colloidal silicon dioxide. The blend is passed through a roller compactor with 25 cm rolls, roll force of 10 kN/cm, gap of 2.0 mm, and roll speed of 12 rpm. Ribbons are granulated through a 1.0 mm screen and then spheronised lightly to reduce fine particles below 150 µm. The resulting granule fraction is filled into stick packs at a target fill weight of 2.0 g, with fill weight uniformity controlled under Ph. Eur. 2.9.5. Water content is determined by Karl Fischer titration according to Ph. Eur. 2.5.32 and is maintained at NMT 2.0% w/w. The terminal dosage form is a dry granule for oral administration and must comply with the release test matrix shown in the table below; dissolution is assessed by USP <711> using a medium selected after pH-solubility screening of the active. Because the long-chain oxalamide has low aqueous solubility, the granule formulation includes a wetting agent in the reconstitution vehicle or within the dry blend when the application permits. This dry-granulation route is suitable for paediatric and geriatric solid-dose presentations where tablet swallowing is not feasible.

When a Lipid-Based Hard Capsule Fill Is Held Above the Melting Point of the API, Reprocessing Is Required

A lipid-based hard-capsule fill containing the compound is susceptible to crystal growth during holding because the active has a long hydrophobic tail and can recrystallise from the molten lipid vehicle when the fill temperature drops below the saturation boundary. The fill is prepared by dispersing the compound in medium-chain triglycerides at 55 °C, with 10.0 mg/g active content and 2.0% w/w soy lecithin as dispersing agent. High-shear dispersion is carried out in a jacketed rotor-stator mixer at 8,000 rpm for 10 min, followed by deaeration under vacuum at 40 kPa. Hard gelatin capsules are filled on a piston-type capsule filling machine with temperature-controlled hoppers maintained at 45 °C to 50 °C. Hold time between dispersion preparation and completion of filling must not exceed 4 h; batch records exceeding this hold time require reheating to 55 °C and re-dispersion before filling. Polarised light microscopy is used for intermediate visual inspection at 100×, and laser diffraction ensures the Dv90 of the dispersed active remains below 80 µm. Capsules are sealed and released under USP <905>, Ph. Eur. 2.9.40, and USP <711>. Elemental impurities are controlled according to ICH Q3D, and the capsule shell supplier must conform to current ICH Q3D risk assessments for gelatin. The terminal dosage form is a hard gelatin capsule containing a lipid-based suspension of the active; this format is operable for low-dose oral administration where the active can be solubilised in the lipid phase and where aqueous granulation would compromise the amorphous or dispersion state of the compound. Published data for this specific lipid dispersion configuration is limited; therefore, crystal formation is monitored by the appearance of birefringent particles and by increased viscosity, and fill processes are qualified using each incoming active lot rather than by literature reference alone.

Wet Bead Milling and Sterile Filtration of an Aqueous Nanosuspension for Injectable Vials

The injectable nanosuspension route is designed around the compound’s poor aqueous solubility and the need to avoid organic solvents in the final formulation. A sterile aqueous vehicle containing 0.5% w/w poloxamer 188 and 10 mM sodium citrate buffer is filtered through a 0.2 µm PVDF membrane. The active is then added aseptically to achieve 25.0 mg/mL and wet bead milled at 2,500 rpm for 45 min using 0.2 mm yttria-stabilised zirconia beads. In-process particle-size measurement by laser diffraction requires a Dv90 below 600 nm and a Dv50 below 250 nm to maintain syringeability and to reduce phagocytic uptake variability. Because the final suspension is not a true solution, sterile filtration of the final nanosuspension may be unsuitable; therefore, aseptic milling is performed inside an ISO 14644-1 Class 5 cleanroom under EU GMP Annex 1 conditions. Terminal sterilisation by moist heat is avoided unless a stability study demonstrates absent amide hydrolysis under the selected thermal cycle. The filled vials are tested for sterility under USP <71> and Ph. Eur. 2.6.1, bacterial endotoxins under USP <85> and Ph. Eur. 2.6.14, and subvisible particulate matter under USP <788> and Ph. Eur. 2.9.19. The terminal dosage form is an injectable nanosuspension in glass vials; it is suitable for parenteral administration when a sustained-release profile is required and when the compound cannot be dissolved in water-miscible cosolvents. The table below summarises the sterile-assurance controls applied to this manufacturing route.

Lyophilised dual-chamber cartridges containing 10.0 mg of the compound per vial are prepared by dissolving the active in a filtered tert-butanol/water cosolvent system because the long-chain oxalamide cannot be dissolved in water alone at sufficient concentration for a pharmaceutically practical fill volume. The solution is filled aseptically into moulded lyophilisation cartridges and frozen at −45 °C for 2 h, followed by an annealing step at −15 °C to promote complete crystallisation of the tert-butanol phase. Primary drying is conducted at 0.1 mbar with shelf temperature raised from −20 °C to 0 °C over 20 h; secondary drying is performed at 30 °C for 6 h until the cake moisture is NMT 1.0% w/w by Karl Fischer titration under USP <921> Method Ic. Residual tert-butanol is controlled under ICH Q3C and confirmed by gas chromatography using USP <467> as the general residual solvents procedure. The terminal dosage form is a lyophilised cake for reconstitution in a dual-chamber cartridge; the reconstitution vehicle is determined by the compatibility of the cartridge plunger with the selected aqueous medium. Sterility is verified under USP <71>, and subvisible particulate matter is tested after reconstitution under USP <788>. The lyophilisation route is selected when the compound is intended for injectable administration but the nanosuspension route is unacceptable due to particle-size distribution drift during storage. Published data for this specific lyophilised configuration is limited; cycle development therefore uses freeze-dry microscopy and heat-flow calorimetry to define the collapse temperature and annealing window for each batch of active. Incompatibility is noted with strongly nucleophilic amine excipients under thermal stress; such combinations should be avoided unless forced-degradation data demonstrate absent adduct formation.

Twin-Screw Extrusion of Reservoir Pellets at Barrel Temperatures Below the Melting Onset

Manufacture of reservoir pellets requires that the compound remain below its melting endotherm during twin-screw extrusion because partial melting of the long-chain oxalamide at the barrel wall produces a greasy interfacial layer that reduces residence-time reproducibility and pellet sphericity. The core formulation contains 15.0% w/w active, 55.0% w/w microcrystalline cellulose, 20.0% w/w ethylcellulose, 5.0% w/w talc, and 5.0% w/w triethyl citrate. Extrusion is performed on a twin-screw extruder with L/D 30:1, screw speed 150 rpm, and barrel temperature zones set from 50 °C to 65 °C; the die plate temperature is maintained below the melting onset determined by differential scanning calorimetry for the incoming active lot. Torque is monitored continuously and must remain below 80% of the drive limit to avoid localised frictional heating above the melting threshold. Extrudate is spheronised at 2,000 rpm for 2 min to produce pellets with mean diameter of 1.0 mm to 1.4 mm. The pellets are then coated in a fluid-bed bottom-spray unit with an aqueous ethylcellulose dispersion to a 10% weight gain, followed by curing at 60 °C for 2 h. Release testing is conducted under USP <711> and content uniformity under USP <905> and Ph. Eur. 2.9.40. Elemental impurities are controlled according to ICH Q3D. The terminal dosage form is a multiple-unit pellet system filled into hard capsules; this format is appropriate for modified-release oral delivery because the active is embedded in an ethylcellulose reservoir rather than being exposed to an immediate-release tablet matrix. Process limitations include the narrow temperature window between the required melt-extrusion zone and the active’s thermal transition; batch records from extended runs show that screw wear exceeding 0.2 mm on the barrel clearance raises torque and destabilises the thermal boundary.

During Aseptic Processing of Oil Depots, the Breakpoint of the Long-Chain Oxalamide Alters Syringeability

Oil-depot injections containing 40.0 mg/mL of the compound are manufactured in a vehicle of sesame oil or medium-chain triglycerides, with 0.5% w/w benzyl alcohol added as a local antimicrobial preservative where permitted by the target pharmacopoeial monograph. The vehicle is heated to 50 °C under aseptic conditions and the API is dissolved with low-shear stirring for 30 min. The solution is filtered through a 0.2 µm sterile membrane and filled into glass vials or pre-filled syringes in an ISO 14644-1 Class 5 aseptic processing suite. Syringeability is measured with a 21-gauge needle and cone-plate viscometer; the formulation is rejected if the viscosity at 25 °C exceeds 40 mPa·s or if the maximum injection force exceeds 20 N at a plunger speed of 10 mm/min. Sterility is confirmed under USP <71>, bacterial endotoxins under USP <85>, and subvisible particles under USP <788> and Ph. Eur. 2.9.19. The terminal dosage form is an injectable oil depot for intramuscular or subcutaneous administration; the high lipid solubility of the active supports extended release from the depot matrix, but the absence of aqueous solubility requires that the clinical formulation be restricted to non-intravenous routes unless terminal sterilisation and stability data are available. The long-chain oxalamide is incompatible with strong aqueous acids and bases under heated conditions; depots should not be blended with aqueous vehicles unless phase separation and amide hydrolysis are evaluated. Manufacturing is governed by USP <1> for injectable drug products, USP <790> for visible particulates, and ISO 11040-4 for pre-filled syringe functional requirements.